| HOME >> BIOLOGY >> TECHNOLOGY |
Table 29: Gastrointestinal Disorder Therapeutics Market, Europe, Revenue ($bn), 2001-2009 30
Table 30: Gastrointestinal Disorder Therapeutics Market, Europe, Revenue ($bn), 2009-2016 30
Table 31: Gastrointestinal Disorder Therapeutics Market, Europe, Annual Cost of Treatment, 2001-2009 31
Table 32: Gastrointestinal Disorder Therapeutics Market, Europe, Annual Cost of Treatment, 2009-2016 31
Table 33: Gastrointestinal Disorder Therapeutics Market, Europe, Diseased Population, 2001-2009 32
Table 34: Gastrointestinal Disorder Therapeutics Market, Europe, Diseased Population, 2009-2016 32
Table 35: Gastrointestinal Disorder Therapeutics Market, Europe, Treatment Seeking Population, 2001-2009 33
Table 36: Gastrointestinal Disorder Therapeutics Market, Europe, Treatment Seeking Population, 2009-2016 33
Table 37: Gastrointestinal Disorder Therapeutics Market, Europe, Diagnosis Population, 2001-2009 34
Table 38: Gastrointestinal Disorder Therapeutics Market, Europe, Diagnosis Population, 2009-2016 34
Table 39: Gastrointestinal Disorder Therapeutics Market, Europe, Prescription Population, 2001-2009 35
Table 40: Gastrointestinal Disorder Therapeutics Market, Europe'/>"/>SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved
Related biology technology :
1. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
2. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
3. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
6. New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinsons Disease
7. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
8. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
9. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
10. SleepQuest Raises Awareness of Sleep Disorders
11. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders